The Safety of Celecoxib as an Acute Treatment for Migraine: A Narrative Review

[1]  P. Hjemdahl,et al.  Lessons from 20 years with COX‐2 inhibitors: Importance of dose–response considerations and fair play in comparative trials , 2022, Journal of internal medicine.

[2]  Á. Lanas,et al.  Gastrointestinal and cardiovascular adverse events associated with NSAIDs , 2021, Expert opinion on drug safety.

[3]  R. Burch,et al.  The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice , 2021, Headache.

[4]  M. Pirmohamed,et al.  Pharmacogenomics of NSAID-Induced Upper Gastrointestinal Toxicity , 2021, Frontiers in Pharmacology.

[5]  H. Diener,et al.  Diagnosis and management of migraine in ten steps , 2021, Nature Reviews Neurology.

[6]  Geun U Park,et al.  Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction. , 2020, Journal of the American College of Cardiology.

[7]  Yiping Wei,et al.  Pros and Cons of Aspirin for the Primary Prevention of Cardiovascular Events: A Secondary Study of Trial Sequential Analysis , 2020, Frontiers in Pharmacology.

[8]  U. Bandyopadhyay,et al.  Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective , 2020, Biochemical Pharmacology.

[9]  R. Lipton,et al.  Efficacy, Tolerability, and Safety of DFN‐15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Study , 2019, Headache.

[10]  C. Cooper,et al.  Safety of Cyclooxygenase-2 Inhibitors in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis , 2019, Drugs & Aging.

[11]  R. de Caterina,et al.  The first 3500 years of aspirin history from its roots - A concise summary. , 2019, Vascular pharmacology.

[12]  A. Roddick,et al.  Association of Aspirin Use for Primary Prevention With Cardiovascular Events and Bleeding Events: A Systematic Review and Meta-analysis , 2019, JAMA.

[13]  C. Walker.  Are All Oral COX-2 Selective Inhibitors the Same? A Consideration of Celecoxib, Etoricoxib, and Diclofenac , 2018, International journal of rheumatology.

[14]  P. Libby,et al.  Effect of Aspirin Coadministration on the Safety of Celecoxib, Naproxen, or Ibuprofen. , 2018, Journal of the American College of Cardiology.

[15]  P. Libby,et al.  Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis , 2018, Arthritis & Rheumatology.

[16]  C. Pepine,et al.  Cardiovascular safety of NSAIDs: Additional insights after PRECISION and point of view , 2017, Clinical cardiology.

[17]  T. Grosser,et al.  The Cardiovascular Pharmacology of Nonsteroidal Anti-Inflammatory Drugs. , 2017, Trends in pharmacological sciences.

[18]  A. Gautam,et al.  Pharmacokinetics of DFN-15, a Novel Oral Solution of Celecoxib, Versus Celecoxib 400-mg Capsules: A Randomized Crossover Study in Fasting Healthy Volunteers , 2017, Clinical Drug Investigation.

[19]  H. Diener,et al.  Medication-overuse headache: risk factors, pathophysiology and management , 2016, Nature Reviews Neurology.

[20]  G. Gislason,et al.  Treatment with non-steroidal anti-inflammatory drugs in patients after myocardial infarction – a systematic review , 2016, Expert opinion on pharmacotherapy.

[21]  Yahiya Y. Syed.  Sumatriptan/Naproxen Sodium: A Review in Migraine , 2015, Drugs.

[22]  D. Buse,et al.  Impact of NSAID and Triptan Use on Developing Chronic Migraine: Results From the American Migraine Prevalence and Prevention (AMPP) Study , 2013, Headache.

[23]  H. Parkman.  Migraine and Gastroparesis From a Gastroenterologist's Perspective , 2013, Headache.

[24]  E. Loder,et al.  The 2012 AHS/AAN Guidelines for Prevention of Episodic Migraine: A Summary and Comparison With Other Recent Clinical Practice Guidelines , 2012, Headache.

[25]  J. Sampalis,et al.  A randomized, double blind, placebo and active comparator controlled pilot study of UP446, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin , 2012, Nutrition Journal.

[26]  M. Lai,et al.  Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): a case-crossover study of Taiwan's National Health Insurance claims database and review of current evidence , 2012, BMC Cardiovascular Disorders.

[27]  P. McGettigan,et al.  Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies , 2011, PLoS medicine.

[28]  M. Egger,et al.  Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis , 2011, BMJ : British Medical Journal.

[29]  J. Schoenen,et al.  NSAIDs in the Acute Treatment of Migraine: A Review of Clinical and Experimental Data , 2010, Pharmaceuticals.

[30]  R. Lipton,et al.  Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: Results from the International Migraine Pain Assessment Clinical Trial (IMPACT) , 2010, Cephalalgia : an international journal of headache.

[31]  T. Grosser,et al.  Emotion recollected in tranquility: lessons learned from the COX-2 saga. , 2010, Annual review of medicine.

[32]  L. G. García Rodríguez,et al.  Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. , 2008, Journal of the American College of Cardiology.

[33]  J. Wallace.  Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? , 2008, Physiological reviews.

[34]  W. Stewart,et al.  Acute Migraine Medications and Evolution From Episodic to Chronic Migraine: A Longitudinal Population‐Based Study , 2008, Headache.

[35]  R. Seymour,et al.  An Evidence-Based Update on Nonsteroidal Anti-Inflammatory Drugs , 2007, Clinical Medicine & Research.

[36]  Kenneth J Rothman,et al.  Use of cyclo‐oxygenase 2 inhibitors (COX‐2) and prescription non‐steroidal anti‐inflammatory drugs (NSAIDS) in UK and USA populations. Implications for COX‐2 cardiovascular profile , 2006, Pharmacoepidemiology and drug safety.

[37]  B. Martin,et al.  Cardiovascular and Cerebrovascular Events in the Randomized, Controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT) , 2006, PLoS clinical trials.

[38]  H. Diener,et al.  Efficacy and Tolerability of Diclofenac Potassium Sachets in Migraine , 2006, Cephalalgia : an international journal of headache.

[39]  P. Sooriakumaran.  COX-2 inhibitors and the heart: are all coxibs the same? , 2006, Postgraduate Medical Journal.

[40]  Sonia Hernández-Díaz,et al.  Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. , 2006, Basic & clinical pharmacology & toxicology.

[41]  E. Wooltorton,et al.  New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra) , 2005, Canadian Medical Association Journal.

[42]  D. Young.  FDA labors over NSAID decisions: panel suggests COX-2 inhibitors stay available. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[43]  J. Lenzer.  FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke , 2005, BMJ : British Medical Journal.

[44]  M. Reilly,et al.  Patients Exposed to Rofecoxib and Celecoxib Have Different Odds of Nonfatal Myocardial Infarction , 2005, Annals of Internal Medicine.

[45]  Thomas Brabant,et al.  The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. , 2005, Archives of internal medicine.

[46]  R. Bonnel,et al.  Comparison of Reporting of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Selective COX-2 Inhibitors , 2005, Drug safety.

[47]  Barbara Sibbald,et al.  Rofecoxib (Vioxx) voluntarily withdrawn from market , 2004, Canadian Medical Association Journal.

[48]  J. Mclaughlin,et al.  Nonselective Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Gastrointestinal Bleeding: Relative and Absolute Risk Estimates From Recent Epidemiologic Studies , 2004, American journal of therapeutics.

[49]  C. Hawkey,et al.  Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors , 2003, Gut.

[50]  K. Brune,et al.  Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal‐salt diet , 2002, Clinical pharmacology and therapeutics.

[51]  R. Hubbard,et al.  Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis , 2001, American Journal of Gastroenterology.

[52]  R. Makuch,et al.  Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. , 2000, JAMA.

[53]  F. Silverstein,et al.  Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor , 2000, American Journal of Gastroenterology.

[54]  J. Vane,et al.  Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[55]  G. FitzGerald,et al.  Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.